JP Morgan Chase
DGX icon

JP Morgan Chase’s Quest Diagnostics DGX Stock Holding History

JP Morgan Chase’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,600
Closed -$1.83M – 7507
2025
Q3 		$1.83M Sell
9,600
-31,800
-77% -$5.64M ﹤0.01% 4150
2025
Q2 		$7.44M Buy
41,400
+39,700
+2,335% +$6.9M ﹤0.01% 2798
2025
Q1 		$288K Buy
+1,700
New +$279K ﹤0.01% 5080
2024
Q3 		– Sell
-25,000
Closed -$3.42M – 7457
2024
Q2 		$3.42M Buy
+25,000
New +$3.42M ﹤0.01% 3338
2020
Q2 		– Sell
-25,400
Closed -$2.04M – 5431
2020
Q1 		$2.04M Buy
+25,400
New +$2.63M ﹤0.01% 2950
2019
Q1 		– Sell
-60,200
Closed -$5.01M – 5807
2018
Q4 		$5.01M Buy
60,200
+12,600
+26% +$1.18M ﹤0.01% 2570
2018
Q3 		$5.14M Buy
+47,600
New +$5.22M ﹤0.01% 2728
2016
Q1 		– Sell
-1,100
Closed -$78K – 4713
2015
Q4 		$78K Buy
+1,100
New +$74K ﹤0.01% 3828

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase's DGX Position: Q2 2026 in Review

JP Morgan Chase reduced its Quest Diagnostics (DGX) stake by 8.5% in Q2 2026, selling an estimated $64M and leaving 3,520,438 shares worth $749M. The position accounts for 0.04% of the portfolio, ranked #346.

JP Morgan Chase first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. The position peaked at $823M in Q3 2025. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • JP Morgan Chase held 3,520,438 shares of Quest Diagnostics worth $749M as of Q2 2026.
  • JP Morgan Chase sold 326,018 Quest Diagnostics shares in Q2 2026, an estimated $64M.
  • Quest Diagnostics made up 0.04% of JP Morgan Chase's portfolio in Q2 2026, its #346 holding.
  • JP Morgan Chase first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Quest Diagnostics position peaked at $823M in Q3 2025.
  • 1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.